Clinical trials: Lymphoma, B-Cell Refractory
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and to see how well they work in treating patients with diffuse large B-cell…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
- Trial name
- NCT02628405
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Academic and Community Cancer Research United
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells.
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT05003141
- Testing
- PSB202
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 110 people
- Sponsor
- Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Lymphoma
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Primary Objective: Overall Response Rate (ORR). Secondary Objectives: The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients and in the responders.
- Trial name
- NCT00493454
- Testing
- Zevalin, Rituximab, ^111 In Ibritumomab Tiuxetan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
This multi-center study open-label trial will enroll a single cohort of relapsed/refractory diffuse large B cell lymphoma (DLBCL) patients whom are ineligible for autologous stem cell transplant (ASCT) due to 1) insensitivity to…
- Trial name
- NCT03305445
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned after a period of…
- Conditions
- Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Prolymphocytic Leukemia
- Trial name
- NCT01886859
- Testing
- Ibrutinib, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Marginal Zone Lymphoma, MZL
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).
- Trial name
- MAGNOLIA (NCT03846427)
- Testing
- Zanubrutinib
- Where
- 31 sites in United States, Australia and 7 more
- Volunteers
- 68 people
- Sponsor
- BeiGene
Diffuse Large B Cell Lymphoma
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.
- Trial name
- R-ICE+X (NCT05348213)
- Testing
- Zanubrutinib plus R-ICE, Decitabine plus R-ICE, Chidamide plus R-ICE
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Ruijin Hospital
Indolent B-cell NHL
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
To compare the efficacy of bendamustine against treatment of physician's choice on progression-free survival in subjects with indolent B-cell NHL.
- Trial name
- ROBIN (NCT01289223)
- Testing
- Bendamustine IV, Treatment of Physicians Choice
- Where
- 3 sites in Australia, Slovakia
- Volunteers
- 88 people
- Sponsor
- Mundipharma Research Limited
Diffuse Large B Cell Lymphoma, CAR-T
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
This is a single-arm single center study to prospectively evaluate the safety and efficacy of ultra-fraction radiotherapy bridging CAR-T therapy in relapsed/refractory diffuse large b cell lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy, Bridging Therapy
- Trial name
- NCT05514327
- Testing
- ultra-fraction radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia)
Stem Cell Transplantation for Patients With Cancers of the Blood
This study will try to improve the safety and effectiveness of stem cell transplant procedures in patients with cancers of the blood.
- Conditions
- CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), AML (Acute Myelogenous Leukemia), Acute Lymphocytic Leukemia
- Trial name
- NCT00467961
- Testing
- Miltenyi system
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
B-Cell Leukemia, B-Cell Lymphoma
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
It is a single-center, open-labeled, single-arm, non-randomized, investigator-initiated trial aiming to evaluate the efficacy and safety of anti-CD19 CAR-T manufactured by OlyCAR platform (OlyCAR-019) for CD19+…
- Conditions
- B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors
- Trial name
- NCT05932173
- Testing
- Anti-CD19 Autologous CAR-T Cell Infusion
- Where
- China
- Volunteers
- 60 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
R/R B-NHL, Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL)
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Evaluate the safety and tolerability of AcNK-Sup003 cell injection in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
- Trial name
- NCT07345741
- Testing
- AcNK-Sup003 cell injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Donghua Zhang
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL)
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be…
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04450069
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Calibr, a division of Scripps Research
Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
This phase II trial studies the effect of zanubrutinib and CAR T-cell therapy in treating patients with aggressive B-cell non-Hodgkin's lymphoma or transformed indolent B-cell lymphoma that has come back (recurrent) or does not…
- Conditions
- Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified, Large B-Cell Lymphoma With IRF4 Rearrangement
- Trial name
- NCT05202782
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Northwestern University
B-cell Non Hodgkin Lymphoma, Richter's Transformation
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
- Trial name
- NCT03778073
- Testing
- Cosibelimab, Cosibelimab + Ublituximab + Bendamustine combination
- Where
- 9 sites in United States
- Volunteers
- 18 people
- Sponsor
- TG Therapeutics, Inc.
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Non-Hodgkin Lymphoma, Follicular Lymphoma
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma…
- Trial name
- NCT05315713
- Testing
- Mosunetuzumab SC, Tiragolumab, Atezolizumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphoma
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine hydrochloride is more effective with or without nutritional…
- Conditions
- Leukemia, Lymphoma, Malnutrition, Myelodysplastic Syndromes
- Trial name
- NCT00949117
- Testing
- Ensure, PediaSure, cyproheptadine hydrochloride
- Volunteers
- 9 people
- Sponsor
- University of South Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.